Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASP
- PDF / 339,419 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 72 Downloads / 171 Views
ORIGINAL ARTICLE
Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry Pieter Vynckier 1 & Giulia Ferrannini 2 & Lars Rydén 2 & Lale Tokgözoğlu 3 & Jan Bruthans 4 & Kornelia Kotseva 5,6 & David Wood 5,6 & Tine De Backer 7 & Sofie Gevaert 7 & Dirk De Bacquer 1 & Delphine De Smedt 1 & On behalf of the EUROASPIRE V Investigators group Accepted: 8 October 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). Methods Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (≥ 6 months to < 2 years after hospitalization) was collected. Results Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%; P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%; P < 0.001) and calcium channel blockers (21.2% vs. 28.8%; P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%; P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%; P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. Conclusion The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients. Keywords EUROASPIRE . Medical treatment . Cardiovascular diseases . Gender
Dirk De Bacquer and Delphine De Smedt should be considered shared senior authors. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10557-020-07095-6) contains supplementary material, which is available to authorized users. * Pieter Vynckier [email protected] 1
2
3
Department of Public Health and Primary Care, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden Department of Cardiology, Hacettepe University, Ankara, Turkey
4
Centre for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University, Prague, Czech Republic
5
National Institute for Prevention and Cardiovascul
Data Loading...
